The Nephrotoxicity of Drugs Used in Causal Oncological Therapies

Round 1

Reviewer 1 Report

Dear Authors,

The paper is very interesting, informative of great importance. It covers the topic comprehensively. There are only minor revisions needed:

- I would recommend updating the list of IO agents approvals - eg. NSCLC or oesophagal cancer for ipilimumab, RCC for pembrolizumab;

- I would rather use "renal cell carcioma" instead of "kidney cancer"

- you have consufsed corticomedullary ratio with cortico-spinal ratio

- "worsening of chronic kidney disease" should be used instead of "intensification of chronic kidney disease"

I recommend check by native speaker. 

Author Response

Thank you very much for your valuable comments. Responding to the questions:

Point 1: I would recommend updating the list of IO agents approvals - eg. NSCLC or oesophagal cancer for ipilimumab, RCC for pembrolizumab;

Response 1: Thank you for the suggestion. We updated the list of IO agents approvals. This comment was applied in the table 1 (indications and mechanism of action ICPs.). 

Point 2: I would rather use "renal cell carcioma" instead of "kidney cancer"
– Thank you for the suggestion. This comment has been included in the text.

Point 3: you have consufsed corticomedullary ratio with cortico-spinal ratio
Response 3: Thank you for the suggestion. This comment has been included in the text.

Point 4:  "worsening of chronic kidney disease" should be used instead of "intensification of chronic kidney disease"
Response4: Thank you for the suggestion. This comment has been included in the text.

Point 5: I recommend check by native speaker. 
Response 5: Thank you for the suggestion. The text was corrected by a certified translator, who translates medical texts for English-language journals.

All valuable comments and suggestions were included in the manuscript.

Yours sincerely,
Sebastian Spaleniak MD,PhD

Reviewer 2 Report

This 19-page review with just one table and 93 references must improve the "Methods" section, explaining better the way of literature search and adding a respective flow-chart according to the PRISMA suggestions (lines 57-62).

Editing should amend some misprints (e.g. nefrotoxicity, line 231), change decimal commas to points (e.g. line 481 or 564), and correct redundancy (e.g. line 556).

Author Response

Thank you very much for your valuable comments. Responding to the questions:

Point 1: This 19-page review with just one table and 93 references must improve the "Methods" section, explaining better the way of literature search and adding a respective flow-chart according to the PRISMA suggestions (lines 57-62).

Response 1: Our article is more a literature review rather than a systematic review, while PRISMA is referred to the systematic reviews and meta-analyses. The search strategy for this literature review has been described in the “Materials and methods” section.

Point 2:  Editing should amend some misprints (e.g. nefrotoxicity, line 231), change decimal commas to points (e.g. line 481 or 564), and correct redundancy (e.g. line 556)

Response 2: Thank you for the suggestion. This comment has been included in the text.

All valuable comments and suggestions were included in the manuscript.

Yours sincerely,
Sebastian Spaleniak MD,PhD